Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi.
Ayvakit's Ascendance | Blueprint's flagship drug Ayvakit drives impressive revenue growth, with projections reaching $2 billion annually by 2030 and potential peak revenue exceeding $4 billion |
Pipeline Promise | Explore Blueprint's diverse pipeline, including BLU-808 for allergic conditions and Elenestinib for indolent systemic mastocytosis, poised to expand market reach |
Financial Trajectory | Analysts expect profitability by late 2026, with current strong cash position of $899.8 million supporting ongoing R&D efforts. Price targets range from $105 to $140 |
Sanofi Synergy | Delve into the implications of Sanofi's acquisition, potentially accelerating Blueprint's growth in precision medicine while navigating integration challenges |
Metrics to compare | BPMC | Peers Peers - average of corresponding metrics from companies closely matching BPMC: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBPMCPeersSector |
---|---|---|---|---|
P/E Ratio | −53.8x | 0.0x | −0.5x | |
PEG Ratio | −1.12 | 0.00 | 0.00 | |
Price/Book | 24.5x | 0.0x | 2.6x | |
Price / LTM Sales | 14.9x | 0.0x | 3.3x | |
Upside (Analyst Target) | −0.4% | 0.0% | 43.5% | |
Fair Value Upside | Unlock | 0.0% | 6.9% | Unlock |